Invest in CSI® Technology: Transforming Neonatal Infection Diagnostics
Overview
Contamination Source Identification® (CSI®) is a CLIA-certified diagnostic laboratory focused on redefining the gold standard of infectious disease diagnostics. To date there are no effective way to diagnose all infections in a timely and precise manner.
To accurately analyze samples for all causes of an infection, CSI® has created a unique system that is not targeted and utilizes a molecular marker of life- RNA. With this method, physicians can receive precise, real-time diagnostic data within approximately 24 hours of sample receipt. To further optimize this testing system, CSI® has also created a proprietary genomic data base and reporting system (RAPID-Dx®) which seamlessly tracks samples from delivery through reporting.
Current Collaborations and Support
Allegheny Health Network (AHN), Highmark, and the Richard King Mellon Foundation have expressed significant interest in supporting our efforts. We are actively writing grant proposals to secure funding for these initiatives. However, to start the Neonatal/Pediatric clinical trial while simultaneously advancing the adult sepsis clinical trial at Geisinger Health System, we require additional funding of $300,000 to $500,000 to bridge to successful grant approval totaling $1.3 million for successful completion of our clinical studies.
Why Your Investment Matters
Sepsis Statistics (CDC):
Incidence: Over 1.7 million people in the U.S. are diagnosed with sepsis annually—one every 20 seconds.
Mortality: Sepsis causes 350,000 deaths per year—one every 90 seconds. This exceeds the deaths from stroke, prostate cancer, breast cancer, and opioid overdose combined.
Hospital Impact: 1 in 3 patients who die in a hospital succumb to sepsis.
Economic Burden: Sepsis has a $64 billion impact on U.S. healthcare costs, more than any other condition.
Neonatal Sepsis:
Incidence: Over 200 children are diagnosed with severe sepsis daily in the U.S., totaling more than 75,000 cases annually.
Mortality: Sepsis is a leading cause of death in children in the U.S., with over 18 deaths daily—more than from all childhood cancers combined.
Neonatal Vulnerability: Neonates have the highest sepsis rates and death from sepsis among all child age groups.
Economic Impact: Caring for children with sepsis in hospitals costs $7.3 billion annually, 18% of all pediatric hospitalization costs.
Antibiotic Overuse: Although neonatal infection rates are only 7%, out of an abundance of caution, 100% of neonates receive antibiotics, with only 14% yielding positive cultures.
Complications:
Development of antibiotic resistance, a worldwide problem
Gut microbiome disruption leading to necrotizing enterocolitis
14% increase in mortality per day on antibiotic regimen
Long-term complications: inflammatory bowel disease, antibiotic resistance, allergies, obesity, diabetes, etc.
The Need for CSI® Technology
Currently, there is no diagnostic for sepsis. CSI® technology provides a critical diagnostic tool that can save lives and reduce healthcare costs by informing physicians accurately and promptly.
Call to Action
We value your interest and support. Please consider helping bridge the funding gap or introducing us to potential investors who can further this important cause. Together, we can revolutionize neonatal and pediatric infection diagnostics and expand the technology's applications and investment opportunities.
Thank you in advance for your support and any assistance you can provide.
